Huntington National Bank Has $3.39 Million Position in Cencora, Inc. (NYSE:COR)

Huntington National Bank lessened its stake in shares of Cencora, Inc. (NYSE:COR) by 1.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,079 shares of the company’s stock after selling 222 shares during the period. Huntington National Bank’s holdings in Cencora were worth $3,394,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. New Millennium Group LLC bought a new position in shares of Cencora during the 2nd quarter worth approximately $26,000. TCTC Holdings LLC acquired a new stake in shares of Cencora during the 1st quarter worth about $29,000. TFO Wealth Partners LLC bought a new position in Cencora during the 1st quarter valued at about $30,000. LRI Investments LLC acquired a new position in Cencora in the first quarter valued at about $31,000. Finally, MFA Wealth Advisors LLC acquired a new position in Cencora in the second quarter valued at about $30,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on COR shares. Wells Fargo & Company boosted their target price on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Leerink Partners dropped their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. JPMorgan Chase & Co. upped their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, UBS Group increased their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Trading Down 2.6 %

Shares of COR stock opened at $243.41 on Friday. The company has a market cap of $47.96 billion, a P/E ratio of 32.41, a PEG ratio of 1.66 and a beta of 0.44. Cencora, Inc. has a fifty-two week low of $191.11 and a fifty-two week high of $251.56. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The stock has a 50 day simple moving average of $232.38 and a two-hundred day simple moving average of $231.00.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. Cencora’s payout ratio is presently 27.16%.

Insider Activity

In related news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now directly owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 7.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 15.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.